Monopar Therapeutics (MNPR) Earnings Analysis

Monopar Therapeutics (MNPR) next reports earnings on 2026-08-11, consensus EPS -0.67 USD. Last quarter (2026-05-14) it beat with EPS -0.46 USD vs -1.06 USD est (+56.6%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -54.34.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MNPR next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.67 USD
Revenue estimaten/a

MNPR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-0.46 USD-1.06 USD+56.6%Beat
2026-03-27-0.61 USD-0.51227 USD-19.1%Miss
2025-11-13-0.48 USD-0.46 USD-4.3%Miss
2025-03-31-2.23 USD-0.36 USD-519.4%Miss
2024-11-08-0.37 USD-0.46 USD+19.6%Beat
2024-08-09-0.5 USD-0.45 USD-11.1%Miss

Beat rate: 2/6 (33%) over reported quarters with consensus data.

MNPR valuation and analyst view

Trailing P/E-54.34
Trailing EPS-1.75571 USD
Price / book7.09
Dividend yield0.00%
Market cap0.75B
Analyst consensusBuy (11 buy / 2 hold / 0 sell)
Avg price target115.4 USD

Related research pages

Frequently asked questions

When is Monopar Therapeutics (MNPR)'s next earnings date?

Monopar Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.67 USD.

Did MNPR beat earnings last quarter?

In its 2026-05-14 report, MNPR posted EPS of -0.46 USD versus a -1.06 USD estimate — a beat of 56.6%.

What is MNPR's earnings track record?

Over the last 6 reported quarters with consensus data, MNPR beat estimates 2 times (33%).

What is MNPR's current P/E ratio and EPS?

MNPR trades at a trailing P/E of -54.34 on trailing EPS of -1.7557084944346808 USD.

What do analysts rate MNPR?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 115.4 USD.